Clinical Trial Update: A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating CBP-201 for efficacy and safety in adults with moderate-to-severe atopic dermatitis has completed, with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• CBP-201

Snippet

Sponsor: Connect Biopharm LLC | Conditions: Moderate-to-severe Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2023-08-01